Skip to main content
Fig. 6 | Breast Cancer Research

Fig. 6

From: Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs

Fig. 6

EGFR (a) and NF-κB (b) pathway-focused RT-PCR gene expression analysis of representative TNBC PDX RNA samples collected before and after Pan-HER treatment. RNA samples corresponding to representative PDX tumor model BCM-2147 (subgroup 2) were extracted from three independent mice (PDX)/group treated with either vehicle control or Pan-HER for 3 cycles at the end of the experiment (day 21 after the initial injection). Triplicate RT-PCR plates were run and relative fold changes of Pan-HER- vs. vehicle control-treated samples for each gene were analyzed by Ingenuity Pathway Analysis (IPA; Qiagen). Genes shown in green represent those significantly downregulated, while those in red upregulated. A twofold change cut-off in gene expression threshold was considered as significantly changed (P < 0.001). Further details, as well as a similar analysis performed in three additional PDX models are shown as Supplemental Figures

Back to article page